Drugs / ATSM COPPER (II)
ATSM COPPER (II)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03204929 | Aug 2017 → Nov 2019 | Parkinson disease | Collaborative Medicinal Development Pty Limited | Completed | No outcome recorded |
| Phase 1 | NCT02870634 | Nov 2016 → Oct 2019 | amyotrophic lateral sclerosis | Collaborative Medicinal Development Pty Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03136809 | Jan 2018 → Dec 2022 | amyotrophic lateral sclerosis | Collaborative Medicinal Development Pty Limited | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04313166 | Mar 2020 → Nov 2021 | amyotrophic lateral sclerosis | Collaborative Medicinal Development Pty Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04082832 Comparator | Sep 2019 → Dec 2020 | amyotrophic lateral sclerosis | Collaborative Medicinal Development Pty Limited | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATSM COPPER (II) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297372 ↗ |
| Known as | Cu(II)ATSM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03204929 ↗ |
| Known as | Cu-atsm | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297372 ↗ |
| Modality | Small molecule | “copper-containing synthetic small molecule” NCT02870634 ↗ |
| Route | Oral | “administered orally once daily” NCT02870634 ↗ |